



FIGHTING DANGEROUS INFECTIONS

CRUCCELL N.V. (CRXL)
A Novel Rabies Vaccine

Crucell is looking forward for developing a rabies treatment with a combination of two human monoclonal antibodies discovered last year using the Company's **MAbstract(r) technology**. It is time for a move from the outdated treatments that are still in use against rabies that kills 55 thousand people each year. The antibody product was discovered by Crucell scientists and characterized in collaboration with Thomas Jefferson University in Philadelphia and the Rabies Section of the Centers for Disease Control and Prevention's (CDC) Division of Viral and Rickettsial Diseases, based in Atlanta.

"This is the first PER.C6(r)-**based protein product** we take into clinical development, following PER.C6(r)-based classical vaccines against influenza and West Nile and adenoviral vaccines against Ebola and Malaria," said Dr Jaap Goudsmit, Crucell's Chief Scientific Officer. "We are proud to pioneer the combination of two human monoclonal antibodies as a potential solution to the problems of cost, availability and safety that currently curtail the success of RIG."

Thanks to its **MAbstract(r) technology** and **PER.C6(r) production technology**, Crucell N.V. has been capable of developing vaccines and antibodies to treat **Ebola, malaria, influenza West Nile virus and rabies** in collaboration with drug companies, NIH and Universities. The company also licenses its PER.C6(r) technology to the biopharmaceutical industry. Licensees include several big and small firms and research institutions.

GOOD NEWS FROM CANADA FOR

OSI (OSIP)
A New Approval for Tarceva

Canadian regulators approved Tarceva as a treatment for advanced or spreading non-small cell lung cancer, in patients who have not responded to chemotherapy. The oral drug, which OSI developed with Genentech Inc. and Roche Holding Ltd., is already approved for this indication in the United States and Switzerland. A European regulatory committee also has recommended approval of the drug.

Separately, yesterday OSI and Genentech said that a study published in The New England Journal of Medicine found that Tarceva's ability to extend patients' lives **does not appear limited to people with certain gene mutations**, as many expected. The journal also published data from a previously announced study that showed Tarceva increased survival in lung cancer patients.

FINAL NOTE

We were pleased to see Standard & Poor's Equity Research raise **Allergan's** price target based on the agreement between this firm and the small biotech drug discovery company Pharmacopoeia. The agreement is to develop compounds to attack abnormal blood vessels that contribute to **age-related macular degeneration**, or AMD. Antiangiogenesis is the name of the big game that was brought at the hands of the biotechnology industry to treat cancer and other diseases, including macular degeneration, the #1 cause of blindness in the elderly.

The increased enthusiasm of Standard & Poor's Equity Research emanated from the fact that the agreement between Allergan and Pharmacopoeia is seen as positive for Allergan, as it would allow it to stay in wet AMD market-share race, competing with **Eyetech Pharmaceuticals (EYET)** and **Genentech** (Lucentis will reach the market soon), which the eye firm badly needs. The agreement also validates Pharmacopoeia's drug discovery technology and increases the degree of confidence in this small firm.



Biotech firms are changing the rules of drug development. It is, indeed, a revolution that investors have to take more seriously than considering investment in just high risk/high reward.

PROHOST RESEARCH
P.O.BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com

FORWARD-LOOKING STATEMENT Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>